B0151005 Open-Label Extension Study

Model scores of the 29,894 trials active now.

Model score 49% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (280 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: extensioncompletedsubjectof studysubjects
  Phrases that lowered it: moderateresponderscrohn diseaseto severepharmacokinetics
• Sponsor's past termination rate: 15.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 372 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 958 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 75 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 6 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 NCT00686374 · started 2008 · scored riskier than 25% of active trials completed
• Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease. NCT02031276 · started 2014 · scored riskier than 29% of active trials completed
• A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease NCT00552344 · started 2008 · scored riskier than 38% of active trials completed
• Open-Label Extension Study of GSK1605786A NCT01318993 · started 2011 · scored riskier than 80% of active trials terminated
• A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease NCT01470599 · started 2012 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.